European Union Approves CBD-Primarily based Seizure Medication


The European Union has authorized a CBD-primarily based medicine as a therapy for seizures connected with two extreme types of epilepsy. The move by regulators with the European Medicines Agency (EMA) marks the very first time a drug derived from cannabis has been authorized for use in Europe. The medication, Epidyolex, is an oral resolution wealthy in cannabidiol, or CBD.

“The approval of EPIDYOLEX® marks a considerable milestone, supplying individuals and their households the very first in a new class of epilepsy medicines and the very first and only EMA-authorized CBD medicine to treat two extreme and life-threatening types of childhood-onset epilepsy,” stated Justin Gover, the CEO of GW Pharmaceuticals, in a press release.

“This approval is the culmination of numerous years of dedication and collaboration amongst GW, physicians and the epilepsy neighborhood,” Gover added. “We think individuals and physicians deserve access to rigorously tested and evaluated cannabis-primarily based medicines, manufactured to the highest requirements and authorized by medicines regulators, and we are delighted to be the very first to give this resolution to the epilepsy neighborhood.”

Drug Presents New Hope

The drug was authorized as an adjunct therapy for individuals with Dravet syndrome and Lennox-Gastaut syndrome, two extreme types of epilepsy that normally seem early in life and can bring about up to hundreds of seizures per day. The medication is authorized for use by individuals two and older in conjunction with clobazam, an current therapy for epilepsy.

Professor Elinor Ben-Menachem of the University of Goteborg’s Sahlgren Academy and Hospital in Sweden stated that the approval of the drug delivers individuals and households hope for improved seizure manage and enhanced high quality of life.

“LGS and Dravet syndrome are two of the most extreme and tough-to-treat types of childhood-onset epilepsy, with handful of individuals reaching sufficient seizure manage,” stated Ben-Menachem.

Isabella Brambilla, the chairman of the Dravet Syndrome European Federation, stated that the approval of the drug is an fascinating achievement for individuals and households eager for a new therapy alternative.

“The approval of cannabidiol oral resolution is an crucial milestone for individuals and households whose lives are drastically impacted by these uncommon, complicated and life-lengthy types of epilepsy,” stated Brambilla.

Drug Also Obtainable in U.S.

Final year, the drug was authorized for use in the United States by the Meals and Drug Administration below the trade name Epidiolex. The Drug Enforcement Administration subsequently relisted Epidiolex below Schedule five of the nation’s list of controlled substances, but the relisting did not apply to other types of cannabidiol.

CBD derived from hemp was legalized in the U.S. with the passage of the 2018 Farm Bill in December. The FDA is presently in the method of formulating regulations for the use of CBD as a supplement or an ingredient in foods.


Latest posts